Exactmer is delighted to announce it has been awarded €2.49M (£2.15M) from the European Innovation Council (EIC) through its Transition programme, to fund ground-breaking research in the synthesis and manufacture of oligonucleotide (oligo) therapeutics. The funding will fast-track the development of new oligo chemistries for Exactmer’s patented Nanostar Sieving technology, which enables the large-scale manufacture of exact polymeric pharmaceuticals.
‘Alternative Chemistry for Oligonucleotide Synthesis using Nanostar Sieving’, ALTOLIGO, will develop innovative synthesis routes to revolutionise the production of oligos, using greener and cheaper methodologies, and alleviating burdensome supply-chains. In contrast to current methodologies, which rely on the classical phosphoramidite approach using solid-phase platforms, Nanostar Sieving employs the liquid phase for synthesis, making the process inherently scalable. Moving away from dependence on solid supports allows for novel, non-classical syntheses to be developed and optimised, pushing the boundaries for efficiency in oligo production.
Exactmer’s CEO, Prof. Andrew Livingston said: “Exactmer is a technology innovator in oligo manufacture. Our Nanostar Sieving platform harnesses over a decade of research at the forefront of membrane technologies, from the Livingston Group at Queen Mary University of London, and provides a step-change in exact polymer manufacturing. This makes it the ideal platform to address the needs of the oligo synthesis market. This EIC Transition funding will enable us to deliver cheaper and more-efficient oligo manufacturing methods, ultimately bringing these innovative therapeutics to all patients in need.”
The EIC Transition programme offers start-ups and small to medium enterprises (SMEs) grants of up to €2.5 million to fund activities that go beyond the experimental proof of principle, addressing both technology and market development. The programme is being financed through the UKRI Horizon Europe Guarantee funding in the UK.
Exactmer began as a spin-out company from Imperial College in December 2017, and is now a fast-growing SME based in Londoneast-UK Technical Park in Dagenham, East London. Contact us at email@example.com if you are interested in partnering on our oligo synthesis work developing through ALTOLIGO, or to find out more about our work in this area.